People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Are you an Ozempic user, or considering starting on the drug? You may want to read this. Recent research is cause for concern ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.